0001209191-23-007563.txt : 20230207 0001209191-23-007563.hdr.sgml : 20230207 20230207164844 ACCESSION NUMBER: 0001209191-23-007563 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 EFFECTIVENESS DATE: 20230207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-472876 FILM NUMBER: 23595763 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 D 1 primary_doc.xml X0708 D LIVE 0001750149 Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE/Ste #1900 Atlanta GA GEORGIA 30339 (678) 392-3419 DELAWARE Inhibikase Therapeutics, LLC None Corporation true Milton H. Werner Ph.D 3350 Riverwood Parkway SE/Ste #1900 Atlanta GA GEORGIA 30339 Executive Officer Director Dennis Berman c/o: Inhibikase Therapeutics, Inc., 3350 Riverwood Parkway SE - Ste. 1900 Atlanta GA GEORGIA 30339 Director Roy Freeman M.D. c/o: Inhibikase Therapeutics, Inc., 3350 Riverwood Parkway SE - Ste. 1900 Atlanta GA GEORGIA 30339 Director Paul Grint, M.D. c/o: Inhibikase Therapeutics, Inc., 3350 Riverwood Parkway SE - Ste. 1900 Atlanta GA GEORGIA 30339 Director Gisele Dion c/o: Inhibikase Therapeutics, Inc., 3350 Riverwood Parkway SE - Ste. 1900 Atlanta GA GEORGIA 30339 Director Joseph Frattaroli, C.P.A. c/o: Inhibikase Therapeutics, Inc., 3350 Riverwood Parkway SE - Ste. 1900 Atlanta GA GEORGIA 30339 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2023-01-27 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue/4th Floor New York NY NEW YORK 10022 All States 4200000 4200000 0 false 1 294000 true 0 0 true Net proceeds may be used for general corporate purposes, including clinical trials and development. true Inhibikase Therapeutics, Inc. /s/ Milton H. Werner Milton H. Werner President & CEO 2023-02-07